Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

TCT 2021 | Outcomes of allogeneic stem cell transplantation in elderly patients

Yngvar Fløisand • 11 Feb 2021
TCT 2021
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes

Yngvar Floisand, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses outcomes associated with allogeneic stem cell transplantation in elderly patients (65 years or above) with acute myeloid leukemia or myelodysplastic syndrome, the findings of which support the use of this treatment approach in elderly patients. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Yngvar Fløisand

Long-term follow-up of a “fast-DC” immunotherapy as a post-remission strategy for AML 4:24
Long-term follow-up of a “fast-DC” immunotherapy as a post-remission strategy for AML
Yngvar Fløisand • 11 Feb 2021

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals